BOD
DEAD

Serial Number

88835504

Owner

Bod Australia Limited

Attorney

Thomas L. Holt

Filing Date

Mar 16, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BOD Trademark

Serial Number: 88835504

BOD is a trademark filed by Bod Australia Limited on March 16, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bod Australia Limited (15 trademarks)

Level 1,

Entity Type: 82

Trademark Details

Filing Date

March 16, 2020

Registration Date

Not Registered

Goods & Services

Nutritional supplements; dietary supplements; vitamin supplements; natural healthcare preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; natural pharmaceutical preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; any the foregoing containing hemp extracts are derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Sep 17, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Sep 17, 2021 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 6, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 6, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 6, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 5, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 5, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 5, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 31, 2020 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Aug 6, 2020 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 6, 2020 PARI
ASSIGNED TO EXAMINER
Jun 9, 2020 DOCK
ASSIGNED TO EXAMINER
Jun 8, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2020 NWOS
NEW APPLICATION ENTERED
Mar 19, 2020 NWAP